NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $41.24 +0.38 (+0.93 %) (As of 02/15/2019 04:00 PM ET)Previous Close$41.24Today's Range$41.04 - $41.3152-Week Range$35.78 - $42.36Volume3.21 million shsAverage Volume3.46 million shsMarket Capitalization$102.30 billionP/E Ratio13.05Dividend Yield4.70%Beta0.79 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom. Receive GSK News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:GSK Previous Symbol CUSIPN/A Webwww.gsk.com Phone44-20-8047-5000Debt Debt-to-Equity Ratio5.52 Current Ratio0.75 Quick Ratio0.51Price-To-Earnings Trailing P/E Ratio13.05 Forward P/E Ratio14.12 P/E Growth2.01 Sales & Book Value Annual Sales$41.14 billion Price / Sales2.49 Cash Flow$4.1953 per share Price / Cash Flow9.83 Book Value$1.98 per share Price / Book20.83Profitability EPS (Most Recent Fiscal Year)$3.16 Net Income$4.84 billion Net Margins11.45% Return on Equity160.39% Return on Assets9.74%Miscellaneous Employees99,349 Outstanding Shares2,480,598,000Market Cap$102.30 billion OptionableOptionable GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions What is GlaxoSmithKline's stock symbol? GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK." How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline? GlaxoSmithKline declared a quarterly dividend on Friday, February 8th. Investors of record on Friday, February 22nd will be paid a dividend of $0.597 per share on Thursday, April 11th. This represents a $2.39 annualized dividend and a yield of 5.79%. The ex-dividend date of this dividend is Thursday, February 21st. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.49. View GlaxoSmithKline's Dividend History. How were GlaxoSmithKline's earnings last quarter? GlaxoSmithKline plc (NYSE:GSK) posted its quarterly earnings data on Wednesday, February, 6th. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.70 by $0.09. The pharmaceutical company earned $10.55 billion during the quarter, compared to analysts' expectations of $9.85 billion. GlaxoSmithKline had a net margin of 11.45% and a return on equity of 160.39%. View GlaxoSmithKline's Earnings History. When is GlaxoSmithKline's next earnings date? GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for GlaxoSmithKline. What price target have analysts set for GSK? 17 Wall Street analysts have issued twelve-month price objectives for GlaxoSmithKline's shares. Their predictions range from $36.95 to $47.00. On average, they expect GlaxoSmithKline's stock price to reach $41.39 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline. What is the consensus analysts' recommendation for GlaxoSmithKline? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 11 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline. Has GlaxoSmithKline been receiving favorable news coverage? News articles about GSK stock have trended somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a news impact score of -1.0 on InfoTrie's scale. They also gave headlines about the pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of GlaxoSmithKline's key competitors? Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG). Who are GlaxoSmithKline's key executives? GlaxoSmithKline's management team includes the folowing people: Ms. Emma Walmsley, CEO & Director (Age 49)Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)Mr. Jack Bailey, Pres of US PharmaceuticalsMs. Karenann K. Terrell, Chief Digital & Technology Officer (Age 58)Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56) Who are GlaxoSmithKline's major shareholders? GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.57%), Bank of America Corp DE (0.31%), Northern Trust Corp (0.11%), Macquarie Group Ltd. (0.10%), Bank of New York Mellon Corp (0.09%) and Brandes Investment Partners LP (0.08%). View Institutional Ownership Trends for GlaxoSmithKline. Which major investors are selling GlaxoSmithKline stock? GSK stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Bank of America Corp DE, Sphera Funds Management LTD., Schafer Cullen Capital Management Inc, Confluence Investment Management LLC, Amundi Pioneer Asset Management Inc., BlackRock Inc. and Brandes Investment Partners LP. View Insider Buying and Selling for GlaxoSmithKline. Which major investors are buying GlaxoSmithKline stock? GSK stock was acquired by a variety of institutional investors in the last quarter, including Boston Partners, Two Sigma Investments LP, Millennium Management LLC, Eversept Partners LP, South Texas Money Management Ltd., Diamond Hill Capital Management Inc., Ferguson Wellman Capital Management Inc. and Hsbc Holdings PLC. View Insider Buying and Selling for GlaxoSmithKline. How do I buy shares of GlaxoSmithKline? Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GlaxoSmithKline's stock price today? One share of GSK stock can currently be purchased for approximately $41.24. How big of a company is GlaxoSmithKline? GlaxoSmithKline has a market capitalization of $102.30 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 99,349 workers across the globe. What is GlaxoSmithKline's official website? The official website for GlaxoSmithKline is http://www.gsk.com. How can I contact GlaxoSmithKline? GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected] MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)Community Ranking: 1.9 out of 5 ()Outperform Votes: 527 (Vote Outperform)Underperform Votes: 884 (Vote Underperform)Total Votes: 1,411MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: How Do Investors Open a Backdoor Roth IRA?